Capoxigem apricoxib: Phase I data

Data from a Phase I trial in 20 patients with recurrent or metastatic NSCLC showed that 150 mg/day oral Tarceva erlotinib in combination with 100, 200 or 400 mg of oral Capoxigem produced 1 partial r...